Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue		$ 2,452	$ 377
Operating expenses:
Cost of revenue		6,420	3,614
Sales and marketing		17,583	19,318
General and administrative		30,947	41,410
Amortization of acquired intangible assets		2,021	1,784
Research and development		14,276	25,338
Total operating expenses		71,247	91,464
Operating loss		(68,795)	(91,087)
Other income (expense):
Interest income		505	169
Interest expense		(589)	(1,281)
Change in fair value - Senior Secured Convertible Notes		(6,026)	(1,273)
Loss on issue and offering costs - Senior Secured Convertible Note		(1,186)	(4,332)
Debt extinguishments loss - Senior Secured Convertible Notes		(3,782)	(5,434)
Change in fair value - derivative liability		(390)
Gain on sale of intellectual property		1,000
Other income (expense), net		(10,468)	(12,151)
Loss before provision for income tax		(79,263)	(103,238)
Provision for income taxes
Net loss before noncontrolling interests		(79,263)	(103,238)
Net loss attributable to the noncontrolling interests		15,088	14,255
Net loss attributable to PAVmed Inc.		(64,175)	(88,983)
Less: Deemed dividend on Series Z warrant modification		(1,791)
Less: Series B Convertible Preferred Stock dividends earned		(304)	(281)
Net loss attributable to PAVmed Inc. common stockholders		$ (66,270)	$ (89,264)
Per share information(1):
Net loss per share attributable to PAVmed Inc. common stockholders - basic	[1],[2]	$ (9.16)	$ (15.03)
Net loss per share attributable to PAVmed Inc. common stockholders - diluted	[1],[2]	$ (9.16)	$ (15.03)
Weighted average common shares outstanding, basic	[2]	7,231,546	5,938,406
Weighted average common shares outstanding, diluted	[2]	7,231,546	5,938,406

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

[2] Reflects the Company’s 1-for-15 reverse stock split that became effective December 7, 2023. Refer to Note 3 - Summary of Significant Accounting Policies for further information.